ERBB2 and cancer: The use of genomic testing or CDK4/6 inhibitors in luminal cancers, double anti-HER2 blockade in HER2-positive and neoadjuvant chemo-immunotherapy in triple-negative tumors are all factors that may make the indicators used somewhat outdated and probably do not reflect good clinical practice, as indicated in the recently published EUSOMA quality indicators update (30).